Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
RESEARCH TOOLSreports
ANRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.00 - $18.35
Previous CloseN/A
Volume104.17K
Average Volume (3M)236.73K
Market Cap
$84.69M
Enterprise Value$143.60M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Mar 20, 2025EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding26,970,167
10 Day Avg. Volume281,552
30 Day Avg. Volume236,728
Standard Deviation0.23
R-Squared0.05
Alpha-0.10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.73
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-384.99
Enterprise Value/Ebitda-2.58
Forecast
1Y Price Target
$15.00Price Target Upside380.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Alto Neuroscience, Inc. News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe interim read confirms that a favorable treatment effect is being observed for ALTO-300, suggesting potential clinical success.
Financial PositionThe company's strong cash position, with $182.2MM available, provides financial runway into 2027, supporting ongoing and future developments.
Market PotentialALTO-300 could generate risk-adjusted net revenue of approximately $1B in the U.S. for Major Depressive Disorder, highlighting its significant market potential.
Bears Say
Non-compliance IssuesHigher-than-anticipated non-compliance was observed in the monotherapy group for '100, affecting the study's outcomes and reliability.
Study DiscontinuationALTO-100 was discontinued in major depressive disorder with poor cognition after missing the primary endpoint in the Phase IIb trial, indicating challenges in the drug's development.
Trial ResultsPhase IIb results for ALTO-100 in major depressive disorder were disappointing, raising concerns about the drug's efficacy.
---
Ownership Overview
18.12% Insiders
10.89% Mutual Funds
33.23% Other Institutional Investors
29.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $3.00 and its highest was $18.35 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Alto Neuroscience, Inc.’s market cap is $84.69M.
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is Mar 20, 2025 which is in 26 days.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Alto Neuroscience, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.65 by $0.03.
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate is -0.65.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 26,970,167 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Alto Neuroscience, Inc. reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.65. Following the earnings report the stock price went up 0.667%.
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Currently, no hedge funds are holding shares in ANRO
---
Alto Neuroscience, Inc. Stock Smart Score
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients¿ brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.
---
ANRO Stock 12 Month Forecast
Average Price Target
$15.00
▲(380.77% Upside)
Technical Analysis
Cytokinetics
―
Minerva Neurosciences
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Mind Medicine
―
Best Analysts Covering ANRO
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-57.11%
reiterated a buy rating 9 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -57.11% per trade.
---